Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free VMD Stock Alerts

Viemed Healthcare (VMD) Competitors

Viemed Healthcare logo
$9.20 +0.03 (+0.33%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$9.18 -0.01 (-0.16%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VMD vs. AMN, PNTG, LMRI, OPK, and CSTL

Should you buy Viemed Healthcare stock or one of its competitors? Viemed Healthcare's main competitors and comparable companies include AMN Healthcare Services (AMN), The Pennant Group (PNTG), Lumexa Imaging (LMRI), OPKO Health (OPK), and Castle Biosciences (CSTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Viemed Healthcare compare to AMN Healthcare Services?

Viemed Healthcare (NASDAQ:VMD) and AMN Healthcare Services (NYSE:AMN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AMN Healthcare Services had 9 more articles in the media than Viemed Healthcare. MarketBeat recorded 12 mentions for AMN Healthcare Services and 3 mentions for Viemed Healthcare. AMN Healthcare Services' average media sentiment score of 0.60 beat Viemed Healthcare's score of 0.54 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Viemed Healthcare has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$301.61M1.16$14.93M$0.3625.56
AMN Healthcare Services$2.73B0.49-$95.70M$2.6812.86

AMN Healthcare Services has a consensus target price of $31.43, suggesting a potential downside of 8.82%. Given AMN Healthcare Services' higher probable upside, analysts clearly believe AMN Healthcare Services is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

Viemed Healthcare has a net margin of 4.81% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Viemed Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
AMN Healthcare Services 3.06%19.92%5.93%

Viemed Healthcare has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Summary

Viemed Healthcare and AMN Healthcare Services tied by winning 8 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to The Pennant Group?

Viemed Healthcare (NASDAQ:VMD) and The Pennant Group (NASDAQ:PNTG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

The Pennant Group has higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$301.61M1.16$14.93M$0.3625.56
The Pennant Group$1.10B1.25$29.58M$0.9043.69

Viemed Healthcare has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, The Pennant Group has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Viemed Healthcare has a net margin of 4.81% compared to The Pennant Group's net margin of 2.93%. The Pennant Group's return on equity of 10.33% beat Viemed Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
The Pennant Group 2.93%10.33%4.20%

In the previous week, The Pennant Group had 4 more articles in the media than Viemed Healthcare. MarketBeat recorded 7 mentions for The Pennant Group and 3 mentions for Viemed Healthcare. The Pennant Group's average media sentiment score of 1.04 beat Viemed Healthcare's score of 0.54 indicating that The Pennant Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
The Pennant Group
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

The Pennant Group has a consensus target price of $41.20, suggesting a potential upside of 4.78%. Given The Pennant Group's stronger consensus rating and higher probable upside, analysts clearly believe The Pennant Group is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
The Pennant Group
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 85.9% of The Pennant Group shares are owned by institutional investors. 20.6% of Viemed Healthcare shares are owned by insiders. Comparatively, 6.9% of The Pennant Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

The Pennant Group beats Viemed Healthcare on 13 of the 16 factors compared between the two stocks.

How does Viemed Healthcare compare to Lumexa Imaging?

Lumexa Imaging (NASDAQ:LMRI) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Viemed Healthcare has a net margin of 4.81% compared to Lumexa Imaging's net margin of 0.00%. Viemed Healthcare's return on equity of 10.16% beat Lumexa Imaging's return on equity.

Company Net Margins Return on Equity Return on Assets
Lumexa ImagingN/A N/A N/A
Viemed Healthcare 4.81%10.16%7.22%

In the previous week, Lumexa Imaging had 6 more articles in the media than Viemed Healthcare. MarketBeat recorded 9 mentions for Lumexa Imaging and 3 mentions for Viemed Healthcare. Lumexa Imaging's average media sentiment score of 0.56 beat Viemed Healthcare's score of 0.54 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lumexa Imaging
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

74.2% of Viemed Healthcare shares are held by institutional investors. 0.7% of Lumexa Imaging shares are held by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viemed Healthcare has lower revenue, but higher earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lumexa Imaging$1.04B1.11-$47.10M-$0.59N/A
Viemed Healthcare$301.61M1.16$14.93M$0.3625.56

Lumexa Imaging currently has a consensus target price of $16.00, suggesting a potential upside of 33.11%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lumexa Imaging is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lumexa Imaging
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Viemed Healthcare
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Viemed Healthcare beats Lumexa Imaging on 9 of the 15 factors compared between the two stocks.

How does Viemed Healthcare compare to OPKO Health?

Viemed Healthcare (NASDAQ:VMD) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 12.32%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
OPKO Health
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Viemed Healthcare has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 20.6% of Viemed Healthcare shares are owned by insiders. Comparatively, 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Viemed Healthcare has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$301.61M1.16$14.93M$0.3625.56
OPKO Health$606.90M1.70-$225.68M-$0.09N/A

Viemed Healthcare has a net margin of 4.81% compared to OPKO Health's net margin of -12.40%. Viemed Healthcare's return on equity of 10.16% beat OPKO Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
OPKO Health -12.40%-5.88%-3.83%

In the previous week, OPKO Health had 4 more articles in the media than Viemed Healthcare. MarketBeat recorded 7 mentions for OPKO Health and 3 mentions for Viemed Healthcare. OPKO Health's average media sentiment score of 0.98 beat Viemed Healthcare's score of 0.54 indicating that OPKO Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
OPKO Health
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Viemed Healthcare beats OPKO Health on 8 of the 15 factors compared between the two stocks.

How does Viemed Healthcare compare to Castle Biosciences?

Viemed Healthcare (NASDAQ:VMD) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 20.6% of Viemed Healthcare shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Viemed Healthcare has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viemed Healthcare
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Viemed Healthcare has a net margin of 4.81% compared to Castle Biosciences' net margin of -5.43%. Viemed Healthcare's return on equity of 10.16% beat Castle Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Viemed Healthcare4.81% 10.16% 7.22%
Castle Biosciences -5.43%-4.15%-3.45%

In the previous week, Viemed Healthcare and Viemed Healthcare both had 3 articles in the media. Castle Biosciences' average media sentiment score of 1.54 beat Viemed Healthcare's score of 0.54 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viemed Healthcare
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Castle Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Viemed Healthcare has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viemed Healthcare$301.61M1.16$14.93M$0.3625.56
Castle Biosciences$357.28M2.53-$24.16M-$0.66N/A

Summary

Viemed Healthcare and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Viemed Healthcare News Delivered to You Automatically

Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VMD vs. The Competition

Export
MetricViemed HealthcareHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$350.41M$9.81B$7.04B$13.07B
Dividend YieldN/A2.55%2.57%10.45%
P/E Ratio25.5635.17270.7225.33
Price / Sales1.164.72574.4274.73
Price / Cash7.96124.3470.4850.90
Price / Book2.403.9412.926.25
Net Income$14.93M$309.96M$3.45B$347.82M
7 Day Performance-5.45%0.09%1.16%1.08%
1 Month Performance-22.56%-0.33%1.38%0.82%
1 Year Performance33.53%19.52%62.53%20.99%

Viemed Healthcare Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VMD
Viemed Healthcare
3.4599 of 5 stars		$9.20
+0.3%		N/A+33.5%$350.41M$301.61M25.561,382
AMN
AMN Healthcare Services
2.0405 of 5 stars		$33.06
-9.7%		$30.86
-6.7%		+85.4%$1.42B$2.73B12.342,664
PNTG
The Pennant Group
3.773 of 5 stars		$38.17
-3.7%		$41.20
+7.9%		+59.2%$1.38B$1.10B42.419,700
LMRI
Lumexa Imaging
3.7882 of 5 stars		$11.66
-0.7%		$16.00
+37.2%		N/A$1.13B$267.73MN/A5,019
OPK
OPKO Health
1.8646 of 5 stars		$1.39
flat		$1.55
+11.5%		+2.2%$1.04B$606.90MN/A1,373

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VMD) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel